Open-label Clinical Trial of Lacosamide in ALS
NCT03186040 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 7
Last updated 2020-07-15
Summary
Lacosamide is administered for patients with amyotrophic lateral sclerosis (ALS).
Conditions
Interventions
- DRUG
-
Lacosamide
Sodium channel blocker
Sponsors & Collaborators
-
Chiba University
lead OTHER
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2017-07-13
- Primary Completion
- 2020-04-30
- Completion
- 2020-05-31
Countries
- Japan
Study Locations
More Related Trials
-
Perampanel for Sporadic Amyotrophic Lateral Sclerosis (ALS)
NCT03019419 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Losmapimod in Subjects With Facioscapulohumeral Muscular Dystrophy (FSHD)
NCT04003974 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT04944784 ·Status: TERMINATED ·Phase: PHASE3
-
Colchicine for Amyotrophic Lateral Sclerosis
NCT03693781 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Evaluating the Safety and Tolerability of QRL-201 in ALS
NCT05633459 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis
NCT02655614 ·Status: COMPLETED ·Phase: PHASE1
-
Platform Trial to Assess the Efficacy of Multiple Drugs in Amyotrophic Lateral Sclerosis (ALS)
NCT06008249 ·Status: TERMINATED ·Phase: PHASE3
-
Safety of Intrathecal Riluzole in Patients With Amyotrophic Lateral Sclerosis
NCT07093268 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT05039099 ·Status: COMPLETED ·Phase: PHASE2
-
NF-κB Inhibition in Amyotrophic Lateral Sclerosis
NCT05031351 ·Status: UNKNOWN ·Phase: PHASE2
-
Dose Titration Study to Test Safety and Effects of CK-2017357 in Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT01486849 ·Status: COMPLETED ·Phase: PHASE2
-
The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS
NCT04391361 ·Status: UNKNOWN ·Phase: PHASE2
-
Trial of Amivita in Amyotrophic Lateral Sclerosis
NCT03103815 ·Status: UNKNOWN ·Phase: NA
-
Arimoclomol in Amyotropic Lateral Sclerosis
NCT03491462 ·Status: COMPLETED ·Phase: PHASE3
-
Ibudilast (MN-166) in Subjects With Amyotrophic Lateral Sclerosis (ALS)
NCT02238626 ·Status: COMPLETED ·Phase: PHASE2
-
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
NCT06673056 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
A Study to Determine the Safety, Pharmacokinetics, and Pharmacodynamics of DNL343 in Participants With Amyotrophic Lateral Sclerosis
NCT05006352 ·Status: COMPLETED ·Phase: PHASE1
-
Minocycline to Treat Amyotrophic Lateral Sclerosis
NCT00047723 ·Status: COMPLETED ·Phase: PHASE3
-
ALS Phase II Study of NX210c
NCT06365216 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Phase 1 ALKS 1140 in Healthy Adults
NCT05019105 ·Status: TERMINATED ·Phase: PHASE1
-
SOD1 Inhibition by Pyrimethamine in Familial Amyotrophic Lateral Sclerosis (ALS)
NCT01083667 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Pivotal Study of N-acetyl-L-leucine for CACNA1A
NCT07221292 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Evaluation of MN-166 (Ibudilast) for 12 Months Followed by an Open-label Extension for 6 Months in Patients With ALS
NCT04057898 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2/PHASE3
-
Neural Stem Cell Treatment for Amyotrophic Lateral Sclerosis (STEMALS)
NCT06344260 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of Nitrazine in the Treatment of ALS
NCT04950647 ·Status: UNKNOWN ·Phase: PHASE2